For Indian pharmaceutical companies operating in the U.S., tax planning is not optional—it’s strategic. Lack of structured tax planning leads to unnecessary tax exposure, pricing inefficiencies, and reduced returns. By aligning U.S. tax strategy with business goals, Indian pharma exporters can strengthen margins, ensure regulatory compliance, and build a scalable presence in the world... https://indamadvisors.com/how-lack-of-us-tax-planning-reduces-profit-margins-for-indian-pharmaceutical/